incrementalNew research
BTK degraders (PROTACs) enter clinical trials for B-cell malignancies
Waldenström's Macroglobulinemia →Summary
BTK degraders such as BGB-16673 and NX-5948 entered clinical trials for B-cell malignancies including WM. Unlike BTK inhibitors which require sustained binding, degraders eliminate the BTK protein entirely via the proteasome. This mechanism may overcome acquired resistance mutations at the BTK C481 binding site that limit covalent BTK inhibitor efficacy.
More from Waldenström's Macroglobulinemia
incrementalTreatment update
Emerging CAR-T and bispecific antibody approaches for WM
significantTreatment update
Pirtobrutinib shows activity in covalent BTK inhibitor-pretreated WM
incrementalNew research
Genomics-guided treatment selection advances in WM
significantTreatment update
Ibrutinib + venetoclax fixed-duration combination in treatment-naive WM
ID: waldenstroms-macroglobulinemia-update-3Type: new_researchImpact: incremental